MAP2K1 and neoplasm: As copper is a cofactor in tumor angiogenesis, and its high levels influence tumor growth [110], Cu agents potentially can be used for BRAFV600E mutation-positive malignancies treatment and tumors resistant to BRAFV600E and MEK1/2 inhibitors [111].